# US 2025/0164502 A1 · Mutant Human Nax Proteins and Screening Methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0164502 A1
- Document ID: US20250164502A1
- Status: Published application
- Kind: A1
- Application number: 18/515,382
- Filed: 2023-11-21
- Published: 2025-05-22
- Earliest claimed: 2021-05-30
- Assignees: Genentech, Inc.; University of Copenhagen
- Applicants: Genentech, Inc.; University of Copenhagen
- Inventors: Cameron L. Noland; Jian Mehr-Dean Payandeh; Stephan Alexander Pless; Han Chow Chua; Marc Kschonsak
- Web page: https://patentgrep.com/patent/US20250164502A1

## CPC

- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- G01N 33/502: {for testing non-proliferative effects}
- G01N 2333/4703: Regulators; Modulating activity
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to mutant human NaX ion channel (“NaX”) proteins and screening methods using a mutant human NaX that may be used to identify molecules that modulate the activity of human NaX. For example, in some embodiments, screening methods involve performing an ion channel assay on a mutant human NaX in the presence of a potential NaX modulator. The disclosure also relates to molecules that act as modulators of human NaX and associated kits for detecting such molecules.

## Claims

### Claim 1

A method of identifying a human NaX ion channel protein (NaX) modulator, comprising:
a) Providing a mutant human NaX wherein at least a portion of the DIII domain of human NaX is replaced by a corresponding portion of the DIII domain of a human or mammalian NaV protein (NaV) and/or comprising a substitution of at least one residue on each of two, three, or four S6 alpha helices of human NaX with a glycine, proline, or polar or charged residue;
b) Performing an ion channel assay on the mutant human NaX in the presence of a potential NaX modulator; and
c) Identifying the potential modulator as a human NaX modulator if the activity of the mutant human NaX in the assay in the presence of the potential modulator is higher or lower than the activity in the absence of the potential modulator.

### Claim 2 (depends on 1)

The method of claim 1, wherein the mutant human NaX comprises all or a portion of the DIII S1-S6 region from a human or mammalian NaV, optionally wherein the at least a portion of the DIII domain of human NaX that is replaced comprises or consists of: (a) DIII (residues 920-1200), (b) DIII voltage-sensor domain III (VSD3) and S4-S5 linker (residues 920-1058), (c) DIII VSD3, S4-S5 linker and S5 (residues 920-1078), (d) DIII and DII-DIII linker (residues 733-1200), (e) DIII and DIII-DIV linker (920-1237), (f) DIII and DII-DIII linker and DIII-DIV linker (733-1237).

### Claim 3 (depends on 1)

The method of claim 1, wherein the at least a portion of the DIII domain of human NaX that is replaced by a corresponding portion of the DIII domain of the human or mammalian NaV (a) does not comprise S5 and/or does not comprise S6 or (b) does not comprise any of S1, S2, S3, S4, and/or S4-S5 linker.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the at least a portion of the DIII domain of human NaX is replaced by a corresponding portion of mammalian Nav1.1, mammalian Nav1.2, mammalian Nav1.3, mammalian Nav1.4, mammalian Nav1.5, mammalian Nav1.6, mammalian Nav1.7, mammalian Nav1.8, mammalian Nav1.9, human Nav1.1, human Nav1.2, human Nav1.3, human Nav1.4, human Nav1.5, human Nav1.6, human Nav1.7, human Nav1.8, or human Nav1.9.

### Claim 6

(canceled)

### Claim 7 (depends on 6)

The method of claim 6, wherein the mutant human NaX comprises the amino acid sequence of one of SEQ ID Nos: 3, 4, 8, 10, 12, 16, or 20.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the mutant human NaX comprises a substitution of at least one residue on two, three, or all four of the four S6 alpha helices with a glycine, proline, or polar or charged residue.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein the mutant human NaX comprises one or two substitutions of an amino acid residue with a glycine, proline, or polar or charged residue within at least two, within at least three, or within each of following segments of SEQ ID NO: 1: residues 383-397 (in S6 of domain I (D1)), residues 717-731 (in S6 of DII), residues 1182-1196 (in S6 of DIII), and/or residues 1485-1499 (in S6 of DIV).

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein the mutant human NaX comprises substitutions of an amino acid residue at two or more or three or more of residues L390, F724, I1189, and I1492 with a glycine, proline, or polar or charged residue.

### Claim 17

(canceled)

### Claim 18 (depends on 16)

The method of claim 16, wherein the mutant human NaX (a) comprises substitutions of amino acid residues L390, F724, and I1189 or of amino acid residues F724, I1189, and I1492 with glycine, proline, or polar or charged residues; (b) comprises substitutions F724Q, I1189T, and I1492T compared to wild-type human NaX; or (c) comprises substitutions L390E, I1189E, and I1492E compared to wild-type human NaX.

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27 (depends on 1)

The method of claim 1, wherein the ion channel assay is a patch clamp or an automated patch clamp assay, an ion flux assay, or an ion- or voltage-sensitive dye assay.

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

A mutant human NaX ion channel (NaX) protein, wherein at least a portion of the DIII domain of human NaX is replaced by a corresponding portion of the DIII domain of a human or mammalian NaV protein (NaV) and/or comprising a substitution of at least one residue on each of the two, three, or four S6 alpha helices with a glycine, proline, or polar or charged residue.

### Claim 33 (depends on 32)

The mutant human NaX of claim 32, wherein the mutant human NaX comprises all or a portion of the DIII S1-S6 region from a human or mammalian NaV, optionally wherein the at least a portion of the DIII domain of human NaX that is replaced comprises or consists of: (a) DIII (residues 920-1200), (b) DIII voltage-sensor domain III (VSD3) and S4-S5 linker (residues 920-1058), (c) DIII VSD3, S4-S5 linker and S5 (residues 920-1078), (d) DIII and DII-DIII linker (residues 733-1200), (e) DIII and DIII-DIV linker (920-1137), (f) DIII and DII-DIII linker and DIII-DIV linker (733-1237).

### Claim 34 (depends on 32)

The mutant human NaX of claim 32, wherein the at least a portion of the DIII domain of human NaX that is replaced by a corresponding portion of the DIII domain of the human or mammalian NaV (a) does not comprise S5 and/or does not comprise S6; or (b) does not comprise any of S1, S2, S3, S4, and/or S4-S5 linker.

### Claim 35

(canceled)

### Claim 36 (depends on 32)

The mutant human NaX of claim 32, wherein the at least a portion of the DIII domain of human NaX is replaced by a corresponding portion of mammalian Nav1.1, mammalian Nav1.2, mammalian Nav1.3, mammalian Nav1.4, mammalian Nav1.5, mammalian Nav1.6, mammalian Nav1.7, mammalian Nav1.8, mammalian Nav1.9, human Nav1.1, human Nav1.2, human Nav1.3, human Nav1.4, human Nav1.5, human Nav1.6, human Nav1.7, human Nav1.8, or human Nav1.9.

### Claim 37

(canceled)

### Claim 38 (depends on 36)

The mutant human NaX of claim 36, wherein the mutant human NaX comprises the amino acid sequence of one of SEQ ID Nos: 3, 4, 8, 10, 12, 16, or 20.

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44 (depends on 32)

The mutant human NaX of claim 32, wherein the mutant human NaX comprises one or two substitutions of an amino acid residue with a glycine, proline, or polar or charged residue within at least two or at least three, or each of following segments of SEQ ID NO: 1: residues 383-397 (in S6 of domain I (D1)), residues 717-731 (in S6 of DII), residues 1182-1196 (in S6 of DIII), and/or residues 1485-1499 (in S6 of DIV).

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47 (depends on 32)

The mutant human NaX of claim 32, wherein the mutant human NaX (a) comprises substitutions of an amino acid residue at two or more of residues L390, F724, I1189, and I1492 with a glycine, proline, or polar or charged residue; (b) comprises substitutions of an amino acid residue at three or more of residues L390, F724, I1189, and I1492 with a glycine, proline, or polar or charged residue; (c) comprises substitutions of amino acid residues L390, F724, and I1189 or of amino acid residues F724, I1189, and I1492 with glycine, proline, or polar or charged residues; (d) comprises substitutions of amino acid residues L390, F724, and I1189 or of amino acid residues F724, I1189, and I1492 with glycine, proline, or polar or charged residues; or (e) comprises substitutions L390E, I1189E, and I1492E compared to wild-type human NaX.

### Claim 48

(canceled)

### Claim 49

(canceled)

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52

A method of determining whether a test molecule that modulates the activity of a human ion channel protein modulates the activity of human NaX ion channel (NaX) protein, comprising:
a) Providing a mutant human NaX in which at least a portion of the DIII domain of human NaX is replaced by a corresponding portion of the DIII domain of a human or mammalian NaV protein (NaV) and/or comprising a substitution of at least one residue on each of two, three, or four S6 alpha helices of human NaX with a glycine, proline, or polar or charged residue;
b) Performing an ion channel assay on the mutant human NaX in the presence of the test molecule; and
c) Determining that the test molecule is a human NaX modulator if the activity of the mutant human NaX in the assay in the presence of the test molecule is higher or lower than the activity in the absence of the test molecule; and optionally,
d) Selecting the test molecule for additional screening if it is not a human NaX modulator according to part (c).

### Claim 53

(canceled)

### Claim 54 (depends on 52, 53)

The method of claim 52 or 53, wherein the mutant human NaX comprises all or a portion of the DIII S1-S6 region from a human or mammalian NaV, optionally wherein the at least a portion of the DIII domain of human NaX that is replaced comprises or consists of: (a) DIII (residues 920-1200), (b) DIII voltage-sensor domain III (VSD3) and S4-S5 linker (residues 920-1058), (c) DIII VSD3, S4-S5 linker and S5 (residues 920-1078), (d) DIII and DII-DIII linker (residues 733-1200), (e) DIII and DIII-DIV linker (920-1237), (f) DIII and DII-DIII linker and DIII-DIV linker (733-1237).

### Claim 55 (depends on 52)

The method of claim 52, wherein the at least a portion of the DIII domain of human NaX that is replaced by a corresponding portion of the DIII domain of the human or mammalian NaV (a) does not comprise S5 and/or does not comprise S6 or (b) does not comprise any of S1, S2, S3, S4, and/or S4-S5 linker.

### Claim 56

(canceled)

### Claim 57 (depends on 52)

The method of claim 52, wherein the at least a portion of the DIII domain of human NaX is replaced by a corresponding portion of mammalian Nav1.1, mammalian Nav1.2, mammalian Nav1.3, mammalian Nav1.4, mammalian Nav1.5, mammalian Nav1.6, mammalian Nav1.7, mammalian Nav1.8, mammalian Nav1.9, human Nav1.1, human Nav1.2, human Nav1.3, human Nav1.4, human Nav1.5, human Nav1.6, human Nav1.7, human Nav1.8, or human Nav1.9.

### Claim 58

(canceled)

### Claim 59 (depends on 52)

The method of claim 52, wherein the mutant human NaX comprises the amino acid sequence of one of SEQ ID Nos: 3, 4, 8, 10, 12, 16, or 20.

### Claim 60

(canceled)

### Claim 61

(canceled)

### Claim 62 (depends on 52)

The method of claim 52, wherein the mutant human NaX comprises a substitution of at least one residue on two, three, or all of the four S6 alpha helices with a glycine, proline, or polar or charged residue.

### Claim 63

(canceled)

### Claim 64

(canceled)

### Claim 65

(canceled)

### Claim 66 (depends on 52)

The method of claim 52, wherein the mutant human NaX comprises one or two substitutions of an amino acid residue with a glycine, proline, or polar or charged residue within at least two, at least three, or within each of following segments of SEQ ID NO: 1: residues 383-397 (in S6 of domain I (D1)), residues 717-731 (in S6 of DII), residues 1182-1196 (in S6 of DIII), and/or residues 1485-1499 (in S6 of DIV).

### Claim 67

(canceled)

### Claim 68

(canceled)

### Claim 69 (depends on 52)

The method of claim 52, wherein the mutant human NaX comprises substitutions of an amino acid residue at two or more or three or more of residues L390, F724, I1189, and I1492 with a glycine, proline, or polar or charged residue.

### Claim 70

(canceled)

### Claim 71 (depends on 52)

The method of claim 52, wherein the mutant human NaX (a) comprises substitutions of amino acid residues L390, F724, and I1189 or of amino acid residues F724, I1189, and I1492 with glycine, proline, or polar or charged residues; (b) comprises substitutions F724Q, I1189T, and I1492T compared to wild-type human NaX; or (c) comprises substitutions L390E, I1189E, and I1492E compared to wild-type human NaX.

### Claim 72

(canceled)

### Claim 73

(canceled)

### Claim 74

(canceled)

### Claim 75

(canceled)

### Claim 76 (depends on 39)

A kit for assaying the activity of human NaX or for identifying a human NaX modulator and/or a molecule that binds to human NaX, comprising the mutant human NaX according to claim 39, and further comprising at least one of: one or more reagents for conducting an ion channel assay, a modulator of the mutant human NaX, and instructions for use.
